LOS ANGELES, August 2026 – BlackLight Surgical, a pioneer in intraoperative cancer detection technologies for interventional oncology, announced that Frank Cheng has been named Chief Executive Officer and a member of the company’s Board of Directors.
“BlackLight’s technology has shown strong potential to change how surgeons see and remove cancer, and to do it without adding a dye or a drug to the surgical procedure,” said Frank Cheng. “I am honored to join our dedicated and highly skilled team. My focus is to carry this technology from today’s FDA Breakthrough Device Designation into the operating rooms where it can help patients.”
“Frank brings exactly the experience we need for this next stage of growth,” said Dr. Keith Black, co-founder and co-Chairman of BlackLight Surgical. “He has built and led multiple medical technology companies through FDA authorization, reimbursement approval and rapid commercial expansion. We are delighted to welcome him as CEO and to the Board.”
Mr. Cheng has spent 30 years in chief executive and senior commercial roles at established and emerging medical technology companies. He began his career at GE Healthcare in diagnostic imaging, then served as Vice President at Roche Diagnostics, leading global business development. He later spent seven years as Senior Vice President and top commercial and operations leader at Stereotaxis, a public robotic surgery company. From 2019 to 2023 he was President and Chief Commercial Officer at Eyenuk, whose autonomous AI diabetic retinopathy technology achieved FDA authorization and Medicare reimbursement approval. From 2023 to 2026 he was CEO of Caristo Diagnostics, where he led the company to FDA authorizations as well as CPT coding and reimbursement approvals for its cardiac imaging and AI technologies.
About BlackLight Surgical
BlackLight Surgical is a pioneer in intraoperative cancer detection technologies for interventional oncology. Developed in collaboration with Cedars-Sinai Medical Center, BlackLight’s system uses dye-free fluorescence imaging to identify cancerous tissue with high precision. The technology has received FDA Breakthrough Device designation. BlackLight’s mission is to help surgeons see cancer clearly during surgery so that patients can be treated successfully with a single operation. For more information, visit bls.life.